NASDAQ:ADIL Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis $0.51 +0.03 (+7.04%) Closing price 04:00 PM EasternExtended Trading$0.54 +0.03 (+4.86%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Adial Pharmaceuticals Stock (NASDAQ:ADIL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Adial Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.47▼$0.5250-Day Range$0.23▼$0.7352-Week Range$0.22▼$1.30Volume2.04 million shsAverage Volume3.35 million shsMarket Capitalization$5.37 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingStrong Buy Company Overview Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. Read More Adial Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreADIL MarketRank™: Adial Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingAdial Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAdial Pharmaceuticals has received no research coverage in the past 90 days.Read more about Adial Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Adial Pharmaceuticals are expected to grow in the coming year, from ($1.53) to ($1.33) per share.Price to Book Value per Share RatioAdial Pharmaceuticals has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Adial Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.48% of the float of Adial Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAdial Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adial Pharmaceuticals has recently increased by 90.51%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdial Pharmaceuticals does not currently pay a dividend.Dividend GrowthAdial Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.48% of the float of Adial Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAdial Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adial Pharmaceuticals has recently increased by 90.51%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News SentimentN/A News SentimentAdial Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Adial Pharmaceuticals this week, compared to 1 article on an average week.Search Interest13 people have searched for ADIL on MarketBeat in the last 30 days. This is an increase of 160% compared to the previous 30 days.MarketBeat Follows18 people have added Adial Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.26% of the stock of Adial Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 16.41% of the stock of Adial Pharmaceuticals is held by institutions.Read more about Adial Pharmaceuticals' insider trading history. Receive ADIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADIL Stock News HeadlinesAdial Pharmaceuticals Regains Compliance with Nasdaq Stockholders’ Equity Listing RequirementJuly 16, 2025 | finance.yahoo.comAdial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing RequirementJuly 16, 2025 | globenewswire.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.July 25 at 2:00 AM | American Alternative (Ad)Adial Pharmaceuticals Files PCT Patent Application to Protect Core ...July 11, 2025 | morningstar.comMAdial Pharmaceuticals Files Update to Provisional Patent ... - NasdaqJuly 11, 2025 | nasdaq.comAdial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045July 9, 2025 | globenewswire.comADIL - Adial Pharmaceuticals Inc News - MorningstarJuly 2, 2025 | morningstar.comMAdial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product SupplyJune 25, 2025 | globenewswire.comSee More Headlines ADIL Stock Analysis - Frequently Asked Questions How have ADIL shares performed this year? Adial Pharmaceuticals' stock was trading at $1.01 on January 1st, 2025. Since then, ADIL shares have decreased by 49.1% and is now trading at $0.5140. How were Adial Pharmaceuticals' earnings last quarter? Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.16. When did Adial Pharmaceuticals' stock split? Shares of Adial Pharmaceuticals reverse split before market open on Monday, August 7th 2023.The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Adial Pharmaceuticals IPO? Adial Pharmaceuticals (ADIL) raised $8 million in an IPO on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager. How do I buy shares of Adial Pharmaceuticals? Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adial Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adial Pharmaceuticals investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD), CymaBay Therapeutics (CBAY), Arista Networks (ANET) and GE Aerospace (GE). Company Calendar Last Earnings5/14/2025Today7/25/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADIL CIK1513525 Webwww.adialpharma.com Phone(434) 422-9800FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Adial Pharmaceuticals$8.00 High Price Target$8.00 Low Price Target$8.00 Potential Upside/Downside+1,456.4%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-218.88% Return on Assets-177.61% Debt Debt-to-Equity RatioN/A Current Ratio1.99 Quick Ratio1.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book0.80Miscellaneous Outstanding Shares10,440,000Free Float9,990,000Market Cap$5.37 million OptionableNo Data Beta1.02 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:ADIL) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.